Sathish Kumar Mungamuri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2400427/publications.pdf

Version: 2024-02-01

33 papers	1,930 citations	361045 20 h-index	476904 29 g-index
33 all docs	33 docs citations	33 times ranked	4016 citing authors

#	Article	IF	Citations
1	Human placental mesenchymal stromal cell therapy restores the cytokine efflux and insulin signaling in the skeletal muscle of obesity-induced type 2 diabetes rat model. Human Cell, 2022, 35, 557.	1.2	3
2	A simple and sensitive liquid chromatographyâ€“tandem mass spectrometry method for quantification of multiâ€residual pesticides in blood. Separation Science Plus, 2022, 5, 193-206.	0.3	2
3	Nanomaterials multifunctional behavior for enlightened cancer therapeutics. Seminars in Cancer Biology, 2021, 69, 178-189.	4.3	29
4	Understanding the Alterations in Lipid Metabolism in NAFLD Progression: Current Trends and Future Directions. Critical Reviews in Oncogenesis, 2021, 26, 35-49.	0.2	8
5	Toxicokinetic analysis of commonly used pesticides using data on acute poisoning cases from Hyderabad, South India. Chemosphere, 2021, 268, 129488.	4.2	10
6	The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems. Scientific Reports, 2021, 11, 16983.	1.6	5
7	Role of epigenetic alterations in aflatoxinâ€induced hepatocellular carcinoma. Liver Cancer International, 2020, 1, 41-50.	0.2	10
8	Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy. Journal of Biological Chemistry, 2019, 294, 16109-16122.	1.6	38
9	Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors: DNA and Histone Modifying Enzymes. , 2019, , 133-157.		0
10	Targeting the epigenome as a therapeutic strategy for pancreatic tumors. , 2019, , 211-244.		0
11	Immunotherapy for Diabetogenic Pancreatitis and Pancreatic Cancer: An Update. , 2019, , 215-236.		0
12	Stabilization of hypoxiaâ€inducible factor 1Î± by cobalt chloride impairs podocyte morphology and slitâ€diaphragm function. Journal of Cellular Biochemistry, 2019, 120, 7667-7678.	1.2	24
13	Hypoxia induces ZEB2 in podocytes: Implications in the pathogenesis of proteinuria. Journal of Cellular Physiology, 2019, 234, 6503-6518.	2.0	27
14	Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. Journal of Immunology, 2018, 201, 1727-1734.	0.4	13
15	Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. Journal of Clinical Investigation, 2018, 128, 5647-5662.	3.9	143
16	USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. Cell Reports, 2016, 14, 2528-2537.	2.9	49
17	CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Molecular Cell, 2016, 63, 526-538.	4.5	58
18	Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget, 2016, 7, 28765-28782.	0.8	43

#	Article	IF	Citations
19	Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters. Oncogene, 2015, 34, 2461-2470.	2.6	22
20	p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene, 2014, 33, 3959-3969.	2.6	88
21	FOXO3â€mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. American Journal of Hematology, 2014, 89, 954-963.	2.0	73
22	Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers. Cell Reports, 2013, 5, 302-313.	2.9	40
23	Î²-Catenin-Independent Activation of TCF1/LEF1 in Human Hematopoietic Tumor Cells through Interaction with ATF2 Transcription Factors. PLoS Genetics, 2013, 9, e1003603.	1.5	60
24	The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes and Development, 2013, 27, 1868-1885.	2.7	61
25	Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. Journal of Experimental Medicine, 2013, 210, 1509-1528.	4.2	181
26	p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nature Structural and Molecular Biology, 2012, 19, 478-484.	3.6	49
27	FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nature Cell Biology, 2011, 13, 1092-1099.	4.6	231
28	p53 Serves as a Host Antiviral Factor That Enhances Innate and Adaptive Immune Responses to Influenza A Virus. Journal of Immunology, 2011, 187, 6428-6436.	0.4	77
29	ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3â^'/â^' mice. EMBO Journal, 2010, 29, 4118-4131.	3.5	126
30	Foxo3 Is Essential for the Regulation of Ataxia Telangiectasia Mutated and Oxidative Stress-mediated Homeostasis of Hematopoietic Stem Cells. Journal of Biological Chemistry, 2008, 283, 25692-25705.	1.6	225
31	Oxidative Stress-Mediated Activation of AKT/mTOR Signaling Pathway Leads to Myeloproliferative Syndrome in FoxO3 Null Mice: A Role for Lnk Adaptor Protein. Blood, 2008, 112, 509-509.	0.6	2
32	Role of mTOR Signaling in Erythropoiesis. Blood, 2008, 112, 3870-3870.	0.6	0
33	Survival Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)â€"Dependent Inhibition of p53. Cancer Research, 2006, 66, 4715-4724.	0.4	233